Immunotherapy Drugs Market to Hit USD 3.01 Billion By 2030, Due to the Rising Demand for Personalized Medicine, says Growth Plus Reports

Newark, New Castle, USA, March 28, 2023 (GLOBE NEWSWIRE) — According to the newest Growth Plus Reports study, the global immunotherapy drugs market is estimated to hit US$ 3.01 billion by 2030, with a revenue CAGR of 7.30%. The study analyzes important strategies, drivers, prospects, competition, market dynamics, market size, data, forecasts, and important investment regions.

Key Takeaways:

• The growing prevalence of cancer and autoimmune diseases will drive market revenue growth.
• Increasing demand for personalized medicine will drive demand for immunotherapy drugs.
• North America dominates the global immunotherapy drugs market. 

Request a Free Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/immunotherapy-drugs-market/7740

                                       Immunotherapy Drugs Market Scope

Market Drivers
The growth in the prevalence of cancer, autoimmune, and infectious diseases will drive the revenue growth of the immunotherapy drugs market. Furthermore, the high adoption of immunotherapy over traditional treatments and the rising demand for personalized medicine will boost the market revenue growth rate. Apart from this, a strong product pipeline and increasing investment in immunotherapy R&D are expected to support the market’s revenue growth.

Market Segmentation
Growth Plus Reports has analyzed the global immunotherapy drugs market from four perspectives: Type, Application, End User, and Region.

Type Segmentation: Based on the type, the global immunotherapy drugs market is segmented into monoclonal antibodies, vaccines, interferons & interleukins, checkpoint inhibitors, and others. The monoclonal antibodies segment dominates the market with the largest revenue share because they’re commonly used in oncology to identify tumor cells and delay or stop their growth.

Application Segmentation: Based on the application, the immunotherapy drugs market is segmented into cancer, infectious diseases, autoimmune & inflammatory diseases, and others. The infectious diseases segment dominates the market because of the emergence of various infectious diseases, including H1N1 and COVID-19.

End-User Segmentation: Based on the end-user, the immunotherapy drugs market is segmented into hospitals, specialty centers, and others. The hospital segment dominates the market because of the high patient footfall and favorable reimbursement policies for immunotherapy.

Regional Growth Dynamics
Based on the region, the global immunotherapy drugs market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

North America leads the immunotherapy drugs market with the largest revenue share. The region’s rising prevalence of various types of cancers and infectious diseases, the presence of prominent players, favorable reimbursement policies, and increasing funding by public and private organizations for developing immunotherapies are attributed to North America’s large revenue share in the market.  

Request for Customization –   https://www.growthplusreports.com/inquiry/customization/immunotherapy-drugs-market/7740

Competitive Landscape

The key players in the global immunotherapy drugs market are:

· Merck & Co., Inc.
· Novartis AG, Pfizer Inc.
· Bristol-Myers Squibb Company 
· Johnson & Johnson Services Inc.
· Bayer AG, GlaxoSmithKline plc 
· F. Hoffmann-La Roche Ltd. 
· AstraZeneca plc 
· Amgen Inc.

The market for immunotherapy drugs is somewhat competitive, with several multinational companies involved. To enhance their market position and market share, market competitors engage in technological advancements, R&D, and mergers and acquisitions.

Recent developments:

• Allogene Therapeutics, Inc., a clinical-stage biotechnology company involved in the development of allogeneic CAR T (AlloCAR T) products for cancer, launched CAR T Together in October 2022, a first-of-its-kind effort comprised of clinical trial investigators who represent the field of clinicians committed to supporting the development of “off-the-shelf” (allogeneic) chimeric antigen receptor (CAR) T products to make CAR T therapy.

• Yescarta, developed by Gilead, was approved by the FDA in April 2022 as the first CAR T-cell therapy for the first treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Table of Content

1. INTRODUCTION
   1. Market Ecosystem
   2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2030
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions
3. PREMIUM INSIGHTS
   1. Current Market Trend (COVID-19 Perspective)
   2. Pipeline Assessment
   3. Key Players & Competitive Positioning (2021) 
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL IMMUNOTHERAPY DRUGS MARKET – ANALYSIS & FORECAST, BY TYPE
   1. Monoclonal Antibodies
   2. Vaccines
   3. Interferons & Interleukins
   4. Checkpoint Inhibitors
   5. Others
6. GLOBAL IMMUNOTHERAPY DRUGS MARKET – ANALYSIS & FORECAST, BY APPLICATION
   1. Cancer
   2. Infectious Diseases
   3. Autoimmune & Inflammatory Diseases
   4. Others

“Immunotherapy Drugs Market TOC”

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-7740

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse related reports:

Pressure Relief Devices Market by Type (Low-Tech Devices, High-Tech Devices), End-user (Hospitals, Ambulatory Surgical Centers) – Global Outlook & Forecast 2023-2031

Pharmaceutical Software Market by Deployment (Cloud-Based, On-Premise), Enterprises (Large Enterprises, Small and Medium-Sized Enterprises), Application (Quality Assurance, Procurement) – Global Outlook and Forecast 2023-2031

Non- Steroidal Anti-Inflammatory Drug Market by Application (Arthritis, Ophthalmic Diseases, Migraine, Others), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Long Term Care Software Market by Product Type (Clinical Software, Non-Clinical Solutions), Mode of Deployment (Web-Based Solutions, On-Premise Solutions, Cloud-Based Solutions), End User (Home Healthcare Agencies, Hospice Care Facilities)- Global Outlook and Forecast 2023-2031

Intra Compartmental Pressure Measuring Systems Market by Method (Slit Catheter, Syringe-based Manometer), End-user (Hospitals, Speciality Clinics) – Global Outlook and Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.